AGO2 and cardiac hypertrophy: Qian et al. (127) found that IGF2BP2 recognizes the m6A modification in the target sequence of miR-133a and subsequently forms a complex with argonaute 2 (AGO2), which promotes the accumulation of miR-133a on the target mRNAs and thus prevents cardiac hypertrophy.